14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AAME vs PASG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Atlantic American Corp (AAME) is the stronger overall head-to-head candidate over Passage Bio, Inc. (PASG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAME carries a Unified Composite Score of 42.1/100 (HOLD) at $1.18 (7.4x Forward P/E, 5.1% operating margin), whereas PASG carries 22.5/100 (STRONG SELL) at $4.13 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAME vs PASG. Trailing 12-month operating profitability (AAME 5.1% vs PASG 0.0%) and valuation multiples (AAME 7.4x vs PASG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $13.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AAME vs PASG Key Questions & Quantitative Answers
As of Nov 16, 2026, Atlantic American Corp (AAME) is the stronger overall head-to-head candidate over Passage Bio, Inc. (PASG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAME carries a Unified Composite Score of 42.1/100 (HOLD) at $1.18 (7.4x Forward P/E, 5.1% operating margin), whereas PASG carries 22.5/100 (STRONG SELL) at $4.13 (N/M Forward P/E, 0.0% operating margin). Technically, AAME sits in a Neutral phase (RSI 48.9, UNCLASSIFIED options structure) and PASG sits in a Neutral phase (RSI 56.7, UNCLASSIFIED options structure).
AAME leads the Growth & Scale pillar: AAME posts +4.8% YoY revenue growth and -59.7% YoY earnings growth on $210M TTM revenue (13.0% gross margin, 5.1% operating margin), compared with PASG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AAME generates $210M in USD-normalized revenue versus N/A for PASG. In operating R&D and SG&A reinvestment, AAME deploys 7.9% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PASG.
AAME screens cheaper on headline valuation multiples. AAME trades at 7.4x Forward P/E, 4.5x Trailing P/E, 2.43x PEG, and 0.1x EV/Revenue (11.5% FCF margin), whereas PASG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAME (5.2% ROE) versus PASG (-212.3% ROE) capital efficiency.
In options market volatility and institutional positioning, AAME carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 116% Vol realized risk). By comparison, PASG carries 0.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.72β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.